Tuesday, September 26, 2023
Chime Biologics has entered into a strategic partnership with Kings Pharm. This collaboration signifies a significant development in the field of biologics, particularly in the context of biosimilar projects.
Under the terms of this agreement, Chime Biologics will utilise its extensive expertise in biosimilar projects to offer a comprehensive range of services to Kings Pharm. These services will encompass cell line development, early-stage process development, global clinical and commercial manufacturing, as well as assistance with the registration process for their biologics products.
This anti-tumour biosimilar is the first collaboration project between Kings Pharm and Chime Biologics to accelerate the development and commercialisation of anti-tumour biosimilar. The exclusive cooperation with Chime Biologics enables to further expand collaboration in the future, all for the benefit of patients.
This collaboration marks the inception of comprehensive biosimilar solution, and support Kings Pharm in bringing its biosimilars to market and enhancing global patient access to biologics.
